Willett, C. G., Boucher, Y., Di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., … Jain, R. K. (2004). Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)). Nature Medicine, 10(6), 649. https://doi.org/10.1038/nm0604-649c

Willett, C. G., Y. Boucher, E. Di Tomaso, D. G. Duda, L. L. Munn, R. T. Tong, D. C. Chung, et al. “Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)).” Nature Medicine 10, no. 6 (January 1, 2004): 649. https://doi.org/10.1038/nm0604-649c.

Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)). Nature Medicine. 2004 Jan 1;10(6):649.

Willett, C. G., et al. “Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)).” Nature Medicine, vol. 10, no. 6, Jan. 2004, p. 649. Scopus, doi:10.1038/nm0604-649c.

Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)). Nature Medicine. 2004 Jan 1;10(6):649.